Form 4: MPM BioVentures Reduces Werewolf Therapeutics Stake

MPM BioVentures 2014 L.P. and affiliated entities reported multiple sales of Werewolf Therapeutics common stock totaling 276,017 shares under a pre-arranged 10b5-1 plan.

Summary

• MPM BioVentures 2014, L.P., along with several affiliated entities, reported the sale of Werewolf Therapeutics, Inc. (HOWL) common stock.
• The transactions occurred on October 27, 2025, October 28, 2025, and October 29, 2025.
• A total of 276,017 shares were disposed of across these three dates.
• The sales were executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• The shares were sold at weighted average prices ranging from $1.51 to $1.82 per share.
• Following these transactions, the reporting persons collectively beneficially own 6,442,653 shares indirectly.
• The reporting persons are identified as 10% owners and directors of Werewolf Therapeutics, Inc.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a major institutional investor and director group. While the sales were pre-planned under a 10b5-1 plan, the reduction in stake and the declining sale prices suggest a lack of strong conviction or a strategic exit, which typically weighs on investor sentiment.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating a structured and pre-planned divestment rather than an immediate reaction to new information.

Negatives

• Significant insider selling by a 10% owner and director group can signal a lack of confidence in the company's near-term prospects.
• The weighted average sale prices declined over the three transaction days, from $1.72 on October 27, 2025, to $1.55 on October 29, 2025, indicating downward price pressure during the selling period.
• The reduction in beneficial ownership by a major institutional investor could lead to negative market sentiment.

Risks

• The continued selling by a major institutional investor could exert further downward pressure on Werewolf Therapeutics' stock price.
• A reduction in stake by a significant shareholder might be interpreted by the market as a signal of potential challenges or limited upside for the company.
• The declining sale prices during the transaction period suggest potential liquidity challenges or a weakening market for the stock.

Future Outlook

The establishment of a Rule 10b5-1 plan indicates a pre-determined strategy by MPM BioVentures to reduce its stake in Werewolf Therapeutics. While these specific transactions are completed, the existence of such a plan suggests a potential for further planned divestments in the future, impacting the long-term ownership structure.

Management Comments

• Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, signed the filing on behalf of the various reporting entities, confirming the transactions.

Industry Context

Werewolf Therapeutics operates in the biotechnology sector, specifically in oncology, as indicated by the involvement of 'MPM Oncology Innovations Fund'. Sales by venture capital or institutional investors like MPM BioVentures are common as funds mature or rebalance portfolios. However, a significant reduction in stake by a 10% owner can be viewed critically, especially if the company is in a crucial development phase or facing market headwinds.

Comparison to Industry Standards

• This filing reports insider trading activity, which is a standard disclosure requirement for public companies. Direct comparison of these specific transactions to industry-wide benchmarks for company performance or project results is not applicable.
• However, the market generally views significant insider selling by a major institutional investor, particularly a 10% owner and director, as a negative signal, regardless of the industry. This is consistent across various sectors, including biotechnology, where investor confidence is crucial.

Related Party Transactions

• MPM BioVentures 2014, L.P. and its affiliated entities (MPM BioVentures 2014 (B), L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM Asset Management Investors BV2014 LLC) are 10% owners and directors of Werewolf Therapeutics, Inc. The reported sales of common stock by these entities constitute related party transactions.

Stakeholder Impact

• Shareholders may perceive the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The company's management might face questions regarding the implications of a major investor reducing its stake.

Next Steps

• Investors will likely monitor future Form 4 filings from MPM BioVentures and its affiliates to assess if this is an ongoing divestment strategy.
• The market will observe Werewolf Therapeutics' stock performance and any subsequent company announcements for factors that might explain or counteract the impact of this insider selling.

Key Dates

Recommendation

The significant reduction in stake by a 10% owner and director group, MPM BioVentures, coupled with declining sale prices, signals a lack of strong conviction from a major institutional investor. While the sales were pre-planned, such a substantial divestment by an insider often precedes periods of underperformance or reflects a strategic decision to exit, making the stock a 'sell' for seasoned investors looking to avoid potential downside.

Keywords

Werewolf Therapeutics, HOWL, MPM BioVentures, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Oncology